What Surgeon-Led Means Without an Operating Theatre

The question patients rightly ask

When a surgeon proposes treating a damaged joint without an operating theatre, a reasonable question follows: if there is no operation, who is actually in charge?

For NanoACi™ — Professor Paul Lee's surgeon-led, non-arthroscopic, needle-delivered, one-stage autologous chondrogenic injection technique — the answer is built into the design. Professor Lee states it directly: 'The innovation is not removing the surgeon. It is removing surgical trauma that no longer needs to be there.' The change is subtractive. The theatre is gone; the specialist is not. Every decision from the first imaging review through to follow-up remains under the surgeon's authority, just as it would in a conventional operative setting.

This matters because 'needle-delivered' can sound, at first reading, like a step down — a procedure handed off to a clinic nurse, or stripped of the rigour that an operating list implies. NanoACi's governing manifesto — 'Keep the surgeon. Keep the science. Remove the arthroscopy.' — is a direct answer to that reading.

The sections that follow show precisely where the surgeon's hand remains throughout, and why the absence of a theatre changes the setting without altering who is responsible.

Every decision point belongs to the surgeon

Surgeon authority over a NanoACi pathway begins well before the session date is set. Case selection is the surgeon's first formal act: Professor Paul Lee reviews each patient's history and determines whether the technique is appropriate for that individual's joint, age, activity level and imaging findings. No procedure is planned without that assessment.

Imaging sits at the centre of the pre-procedure stage. MRI review is conducted by the surgeon directly, not passed to a reporting service and acted on secondhand. The clinical picture that emerges — the lesion size, location and surrounding tissue — informs every downstream decision, from the precise delivery approach to the post-procedure plan.

The session itself is a sequence of technical acts, each performed by the surgeon personally. Blood is drawn and processed into autologous platelet-rich fibrin using a sealed automated system. Three small punches are taken from the concha of the ear under local anaesthetic. The complete construct is then delivered by needle, with the surgeon guiding each step. The patient is awake throughout in a clinic room; the absence of a theatre does not alter who is holding the instruments.

After the session, specialist oversight continues into follow-up. Progress is monitored by the same surgeon who made the initial selection, reviewed the scans and performed the procedure — preserving the continuity of judgement that defines a managed clinical pathway rather than a one-off intervention.

Inside the clinic-room session

Three preparation streams run in parallel within a single clinic-room sitting — no laboratory gap, no second visit to unite the components. The result is a construct assembled entirely at point of care, by the surgeon, in the same room as the patient.

Each element carries a defined biological role. The autologous auricular cartilage micrografts serve as seed: mechanically prepared from the concha samples, they bring chondrogenic potential from a donor site whose perichondrium holds more progenitor-cell density than joint cartilage. The cell-free native type I collagen matrix — ChondroFiller — acts as scaffold, providing the structural environment into which the micrografts are placed. Autologous PRF is the signal: processed from the patient's own blood within the same session, it delivers growth factors and a fibrin architecture that support the regenerative environment.

Combining all three in one sitting — with none outsourced to an external laboratory — means the surgeon retains direct oversight of the complete biological construct from preparation through to delivery. At no point does the material leave the room or pass through a stage the surgeon has not personally managed.

Needle delivery is the access route for that construct: the means by which a technically prepared, three-component assembly reaches the treatment site. The approximately 30-minute session is dense with preparation; the needle is where that preparation ends, not where clinical complexity is set aside.

Why the operating theatre was the part that could leave

A general anaesthetic keeps a patient still during arthroscopic access. A sterile operating environment manages the contamination risk that open instruments bring to an exposed joint. A second hospital admission reunites the patient with laboratory-cultured cells weeks after the first procedure. Each of these provisions is right for arthroscopic surgery — and none is required by the NanoACi construct.

The three components — micrografts, collagen matrix and PRF — can be prepared entirely at point of care within a single session. There is no enzyme digestion step, no clean-room culture interval, no external laboratory to wait for. The biology of the construct does not call for those conditions, so the infrastructure that supports them is not needed.

The choice of auricular cartilage follows the same logic. The perichondrium surrounding the ear concha holds a higher density of progenitor cells than joint cartilage; gram for gram, it carries more regenerative potential than the surface being treated. Three 2.5 mm punches, taken under local anaesthetic, are all the harvest requires. The donor site heals within approximately a week. Harvesting from the joint itself would disturb the tissue the procedure aims to restore — the ear sidesteps that problem entirely.

PRF adds its biological signal from the same session: the patient's own blood, drawn and processed on the day, with no external handling at any stage.

The manifesto 'Keep the surgeon. Keep the science. Remove the arthroscopy.' frames this precisely. What was subtracted from the traditional model was never part of the biology of cartilage repair — it was part of a surgical access route that this construct does not use.

Where conventional ACI hands control to the laboratory

Conventional ACI is well-established care, designed around biology that genuinely demands two hospital visits. The first procedure harvests a small cartilage sample; those cells then travel to an external laboratory, where technicians culture them over several weeks before the second admission, the second general anaesthetic, and the implantation. Both procedures are surgeon-led. The interval between them, however, is not: the biological process during cell culture sits entirely outside the operating surgeon's hands, in a clean-room environment the surgeon neither enters nor controls.

That is not a design flaw. It is what two-stage cell culture structurally requires. The laboratory stage exists because the biology demands it — and the two-stage model remains appropriate for presentations where that depth of preparation is indicated.

What NanoACi changes is the architecture. By building a three-component construct from materials that need no cell culture, no enzyme digestion, and no external handling, the technique removes the interval entirely. Surgeon authority runs continuously — from case selection through to needle delivery — without a weeks-long handover to a facility the surgeon does not govern. The key distinction, then, is not that one approach uses a theatre and the other does not. It is that one process architecture contains an inherent gap in surgical oversight, and the other is designed so that no such gap can exist.

Measuring what surgeon-led achieves

NanoACi 100 is the prospective programme through which combined-protocol outcomes are compiled — a structured mechanism for tracking what seed, scaffold and signal achieve together across the full patient pathway. Component evidence for the collagen matrix and PRF is already established within published literature; NanoACi 100 builds the combined layer that reflects the technique as it is actually delivered, in a single planned sitting, under continuous specialist oversight.

Surgeon-led design has a particular consequence for that evidence gathering. The specialist who selects the patient, prepares the construct and delivers it by needle is the same specialist who monitors the result. There is no laboratory interval interposed between procedure and follow-up — accountability is continuous, and so is the clinical picture.

That continuity is what 'surgeon-led without an operating theatre' means in practice. Removing the arthroscopy simplified the access route and shortened the patient's sitting. It left the clinical structure — case selection, delivery, measurement, follow-up — entirely intact. The innovation was the surgery taken away; what remains is specialist judgement applied at every stage, including the one that asks how well the repair is holding.

Patients whose joint pain has raised the question of whether something can be done without a major operation will find that a scan review or specialist consultation is the right first step — and that the surgeon who answers the question is the same one who will see it through.